Potential antiviral effects of the marine probiotic Paraliobacillus zengyii on the respiratory syncytial virus

Abstract

Probiotics can reduce the incidence of respiratory syncytial virus (RSV) disease in premature infants; this approach is resource-intensive and less expensive than other strategies and easier to implement than most current methods worldwide. Traditional lactic acid-producing bacteria are the main probiotics that have been studied for RSV treatment. Marine probiotics promote the survival, immunity, and disease resistance of aquatic plants and animals. However, relatively little research has been conducted on viral infections in humans. Here, we report a slightly halophilic and extremely halotolerant marine bacterium, Paraliobacillus zengyii, which has antiviral activity and grows at a relatively low temperature (28°C). We found that P. zengyii inhibited RSV infection by regulating the interferon (IFN) response both in vitro and in vivo. P. zengyii significantly increased the RSV-induced phosphorylation of TBK1 and IRF3 and the expression of antiviral factors interferon-induced transmembrane protein 1 (IFITM1) and interferon-induced transmembrane protein 3 (IFITM3). Furthermore, P. zengyii upregulated Sendai virus (SeV)- and poly(I:C)-induced IFN-β expression. These results indicate that the marine bacterium P. zengyii inhibits RSV infection and increases IFN-β production in response to RSV, SeV infection, or poly(I:C) stimulation. Consequently, P. zengyii has potential as a broad-spectrum anti-RNA virus probiotic.

Keywords

antiviral activity / marine probiotics / Paraliobacillus zengyii / respiratory syncytial virus / type I interferon

References

[1] Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017; 14: 491-502.

[2] Eze OC, Berebon DP, Emencheta SC, Evurani SA, Okorie CN, Balcão VM, et al. Therapeutic potential of marine probiotics: a survey on the anticancer and antibacterial effects of pseudoalteromonas spp. Pharmaceuticals. 2023; 16: 1091.

[3] Chang M, Wang F, Ma F, Jin Y, Sun P. Supplementation with galacto-oligosaccharides in early life persistently facilitates the microbial colonization of the rumen and promotes growth of preweaning Holstein dairy calves. Anim Nutr. 2022; 10: 223-233.

[4] Stavropoulou E, Bezirtzoglou E. Probiotics in medicine: a long debate. Front Immunol. 2020; 11: 2192.

[5] Li B, Pan LL, Sun J. Novel probiotic lactic acid bacteria were identified from healthy infant feces and exhibited anti-inflammatory capacities. Antioxidants. 2022; 11: 1246.

[6] Azam MW, Khan AU. CRISPRi-mediated suppression of E. coli Nissle 1917 virulence factors: a strategy for creating an engineered probiotic using csgD gene suppression. Front Nutr. 2022; 9: 938989.

[7] Ravi AV, Musthafa KS, Jegathammbal G, Kathiresan K, Pandian SK. Screening and evaluation of probiotics as a biocontrol agent against pathogenic Vibrios in marine aquaculture. Lett Appl Microbiol. 2007; 45: 219-223.

[8] Madison D, Schubiger C, Lunda S, Mueller RS, Langdon C. A marine probiotic treatment against the bacterial pathogen Vibrio coralliilyticus to improve the performance of Pacific (Crassostrea gigas) and Kumamoto (C. sikamea) oyster larvae. Aquaculture. 2022; 560: 738611.

[9] Ishikawa M, Ishizaki S, Yamamoto Y, Yamasato K. Paraliobacillus ryukyuensis gen. nov., sp. nov., a new Gram-positive, slightly halophilic, extremely halotolerant, facultative anaerobe isolated from a decomposing marine alga. J Gen Appl Microbiol. 2002; 48: 269-279.

[10] Kumova OK, Fike AJ, Thayer JL, Nguyen LT, Mell JC, Pascasio J, et al. Lung transcriptional unresponsiveness and loss of early influenza virus control in infected neonates is prevented by intranasal Lactobacillus rhamnosus GG. PLoS Pathog. 2019; 15: e1008072.

[11] Yuen CK, Lam JY, Wong WM, Mak LF, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020; 9: 1418-1428.

[12] Novak T, Hall MW, McDonald DR, Newhams MM, Mistry AJ, Panoskaltsis-Mortari A, et al. RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness. J Allergy Clin Immunol. 2020; 145: 1673-1680.e11.

[13] Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D,., Thompson R. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014; 6: 217-225.

[14] Tran DM, Tran TT, Phung TTB, Bui HT, Nguyen PTT, Vu TT, et al. Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection. Sci Rep. 2022; 12: 12402.

[15] Tomosada Y, Chiba E, Zelaya H, Takahashi T, Tsukida K, Kitazawa H, et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol. 2013; 14: 40.

[16] Rossi GA, Ballarini S, Silvestri M, Sacco O, Colin AA. Respiratory syncytial virus and airway microbiota - a complex interplay and its reflection on morbidity. Pediatr Allergy Immunol. 2021; 32: 1141-1151.

[17] Zhang W, Zhang L, Zan Y, Du N, Yang Y, Tien P. Human respiratory syncytial virus infection is inhibited by IFN-induced transmembrane proteins. J Gen Virol. 2015; 96: 170-182.

[18] Sun Y, Jain D, Koziol-White CJ, Genoyer E, Gilbert M, Tapia K, et al. Immunostimulatory defective viral genomes from respiratory syncytial virus promote a strong innate antiviral response during infection in mice and humans. PLoS Pathog. 2015; 11: e1005122.

[19] Vignuzzi M, López CB. Defective viral genomes are key drivers of the virus-host interaction. Nat Microbiol. 2019; 4: 1075-1087.

[20] Foronjy RF, Ochieng PO, Salathe MA, Dabo AJ, Eden E, Baumlin N, et al. Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations. Mucosal Immunol. 2016; 9: 1317-1329.

[21] Kanmani P, Kim H. Immunobiotic strains modulate Toll-like receptor 3 agonist induced innate antiviral immune response in human intestinal epithelial cells by modulating IFN regulatory factor 3 and NF-κB signaling. Front Immunol. 2019; 10: 1536.

[22] Romero-Arguelles R, Tamez-Guerra P, González-Ochoa G, Romo-Sáenz CI, Gomez-Flores R, Flores-Mendoza L, et al. Bifidobacterium longum and Chlorella sorokiniana improve the IFN type I-mediated antiviral response in rotavirus-infected cells. Microorganisms. 2023; 11: 1237.

[23] Schreiber G. The molecular basis for differential type I interferon signaling. J Biol Chem. 2017; 292: 7285-7294.

[24] Miyakawa K, Nishi M, Ogawa M, Matsunaga S, Sugiyama M, Nishitsuji H, et al. Galectin-9 restricts hepatitis B virus replication via p62/SQSTM1-mediated selective autophagy of viral core proteins. Nat Commun. 2022; 13: 531.

[25] Meischel T, Fritzlar S, Villalon-Letelier F, Tessema MB, Brooks AG, Reading PC, et al. IFITM proteins that restrict the early stages of respiratory virus infection do not influence late-stage replication. J Virol. 2021; 95: e0083721.

[26] Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, et al. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One. 2013; 8: e80723.

[27] Zuo Y, He J, Liu S, Xu Y, Liu J, Qiao C, et al. LATS1 is a central signal transmitter for achieving full type-I interferon activity. Sci Adv. 2022; 8: eabj3887.

[28] Antunes KH, Fachi JL, de Paula R, da Silva EF, Pral LP, dos Santos AÁ, et al. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. Nat Commun. 2019; 10: 3273.

[29] Brown JA, Sanidad KZ, Lucotti S, Lieber CM, Cox RM, Ananthanarayanan A, et al. Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut Microbes. 2022; 14: 2105609.

[30] Wang X, Yang J, Lu S, Lai XH, Jin D, Pu J, et al. Paraliobacillus zengyii sp. nov., a slightly halophilic and extremely halotolerant bacterium isolated from Tibetan antelope faeces. Int J Syst Evol Microbiol. 2019; 69: 1426-1432.

[31] Cao WR, Guo LY, Du ZJ, Das A, Saren G, Jiang MY, et al. Paraliobacillus sediminis sp. nov., isolated from East China sea sediment. Int J Syst Evol Microbiol. 2017; 67: 1577-1581.

[32] Li H, Ren H, Cao L, Guo J, Song J, Zhang Y, et al. Establishment and application of a lethal model of an HRSV-long variant strain in BALB/c mice. Exp Anim. 2022; 71: 500-509.

[33] Miller MS, Rialdi A, Ho JSY, Tilove M, Martinez-Gil L, Moshkina NP, et al. Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis. Nat Immunol. 2015; 16: 485-494.

[34] Stefan KL, Kim MV, Iwasaki A, Kasper DL. Commensal microbiota modulation of natural resistance to virus infection. Cell. 2020; 183: 1312-1324.e10.

[35] Li R, Li Y, Kristiansen K, Wang J. SOAP: short oligonucleotide alignment program. Bioinformatics. 2008; 24: 713-714.

[36] Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9: 357-359.

[37] Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12: 323.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.